+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Age-related Macular Degeneration Market by Route Of Administration, Treatment, Drug Class, Type, End User, Distribution Channel, Stage - Global Forecast to 2030- Product Image
Age-related Macular Degeneration Market by Route Of Administration, Treatment, Drug Class, Type, End User, Distribution Channel, Stage - Global Forecast to 2030- Product Image
Sale

Age-related Macular Degeneration Market by Route Of Administration, Treatment, Drug Class, Type, End User, Distribution Channel, Stage - Global Forecast to 2030

  • PDF Icon

    Report

  • 192 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5665786
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Age-related Macular Degeneration (AMD) market is undergoing significant evolution, driven by therapeutic advancements, demographic shifts, and strategic realignments across the healthcare ecosystem. Senior decision-makers face a fast-changing landscape with new opportunities and complex challenges around product innovation, regulatory shifts, and global supply dynamics.

Market Snapshot: Age-related Macular Degeneration Market

The Age-related Macular Degeneration Market grew from USD 11.10 billion in 2024 to USD 11.82 billion in 2025. It is expected to continue growing at a CAGR of 6.75%, reaching USD 16.43 billion by 2030. This growth is propelled by increasing AMD prevalence, advances in treatment technologies, and greater healthcare investment. The market’s trajectory reflects strong demand from both developed and emerging health systems seeking to manage the growing burden of AMD while navigating evolving regulatory and commercial considerations.

Scope & Segmentation

  • Route of Administration: Implant, Intravitreal Injection
  • Treatment Modalities: Non-Pharmacological (Laser Therapy, Photodynamic Therapy), Pharmacological (Anti-VEGF, Corticosteroids)
  • Drug Classes: Anti-VEGF (Aflibercept, Bevacizumab, Brolucizumab, Ranibizumab), Corticosteroids (Dexamethasone, Triamcinolone)
  • Type: Dry (Geographic Atrophy), Wet
  • End Users: Clinics, Hospitals, Specialty Ophthalmic Centers
  • Distribution Channels: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
  • Disease Stage: Early, Intermediate, Late
  • Regions Covered: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East, Africa (spanning UK, Germany, France, and others), Asia-Pacific (including China, India, Japan, Australia, and key Southeast Asian markets)
  • Notable Manufacturers & Innovators: Regeneron Pharmaceuticals, Bayer AG, Novartis AG, Roche Holding, Alcon Inc., Carl Zeiss Meditec, Topcon Corporation, Nidek, Heidelberg Engineering, Optos plc

Key Takeaways

  • Breakthroughs in molecular targeting, gene therapy, and extended-release delivery are reshaping AMD treatment options and improving patient adherence.
  • Emergence of digital diagnostics, tele-ophthalmology, and remote monitoring platforms offer pathways to earlier detection and more efficient patient management.
  • Market competition continues to intensify as agile biotechnology firms and established players pursue innovation through licensing, partnerships, and technological integration such as AI-enabled imaging.
  • Complex reimbursement and procurement models, influenced by region-specific policy and insurance frameworks, have a direct impact on product rollout and adoption.
  • Unmet needs persist, particularly in treatments for geographic atrophy and early-stage disease, spurring ongoing R&D focused on complement inhibitors and neuroprotective agents.
  • Customized commercialization strategies and omnichannel distribution are vital to ensure consistent product accessibility across the spectrum of healthcare settings.

Tariff Impact on Supply Chain and Access

Newly implemented U.S. tariffs in 2025 affecting ophthalmic devices and specialized pharmaceuticals are increasing input costs and altering global supply chain strategies. Manufacturers are revisiting sourcing decisions, deploying diversified supplier networks, and, in some cases, relocating production to minimize disruption. Healthcare providers are also restructuring reimbursement arrangements and service packages to balance the economic impact. These dynamics can create competitive openings for domestic producers and require industry leaders to maintain commercial agility as policies evolve.

Methodology & Data Sources

This analysis utilizes a robust framework, blending primary research from key opinion leaders and clinical practitioners with secondary data such as regulatory filings, industry databases, and published scientific studies. Market segmentation and pipeline dynamics are validated through cross-verification, ensuring a multi-dimensional perspective for strategic planning.

Why This Report Matters

  • Enables leadership to anticipate emerging trends and intervention opportunities, supporting more informed strategic decisions in the AMD market.
  • Facilitates understanding of complex market segmentation and regional variations, optimizing product positioning and go-to-market approaches.
  • Mitigates risk by mapping the interplay between regulatory shifts, tariff impacts, and evolving technology landscapes relevant to senior decision-makers.

Conclusion

The AMD market is positioned for diverse growth, marked by rapid therapeutic and technological innovation. Stakeholders who align their strategies with emerging trends and regional requirements will be best placed to capture new market opportunities and drive sustained success.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Age-related Macular Degeneration Market, by Route Of Administration
8.1. Introduction
8.2. Implant
8.3. Intravitreal Injection
9. Age-related Macular Degeneration Market, by Treatment
9.1. Introduction
9.2. Non-Pharmacological
9.2.1. Laser Therapy
9.2.2. Photodynamic Therapy
9.3. Pharmacological
9.3.1. Anti-Vegf
9.3.1.1. Aflibercept
9.3.1.2. Bevacizumab
9.3.1.3. Brolucizumab
9.3.1.4. Ranibizumab
9.3.2. Corticosteroid
9.3.2.1. Dexamethasone
9.3.2.2. Triamcinolone
10. Age-related Macular Degeneration Market, by Drug Class
10.1. Introduction
10.2. Anti-Vegf
10.2.1. Aflibercept
10.2.2. Bevacizumab
10.2.3. Brolucizumab
10.2.4. Ranibizumab
10.3. Corticosteroid
10.3.1. Dexamethasone
10.3.2. Triamcinolone
11. Age-related Macular Degeneration Market, by Type
11.1. Introduction
11.2. Dry
11.2.1. Geographic Atrophy
11.3. Wet
12. Age-related Macular Degeneration Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Hospitals
12.4. Specialty Ophthalmic Centers
13. Age-related Macular Degeneration Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacy
13.3. Online Pharmacy
13.4. Retail Pharmacy
14. Age-related Macular Degeneration Market, by Stage
14.1. Introduction
14.2. Early
14.3. Intermediate
14.4. Late
15. Americas Age-related Macular Degeneration Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Age-related Macular Degeneration Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Age-related Macular Degeneration Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Regeneron Pharmaceuticals, Inc.
18.3.2. Bayer AG
18.3.3. Novartis AG
18.3.4. Roche Holding AG
18.3.5. Alcon Inc.
18.3.6. Carl Zeiss Meditec AG
18.3.7. Topcon Corporation
18.3.8. Nidek Co., Ltd.
18.3.9. Heidelberg Engineering GmbH
18.3.10. Optos plc
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. AGE-RELATED MACULAR DEGENERATION MARKET MULTI-CURRENCY
FIGURE 2. AGE-RELATED MACULAR DEGENERATION MARKET MULTI-LANGUAGE
FIGURE 3. AGE-RELATED MACULAR DEGENERATION MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2024 VS 2030 (%)
FIGURE 10. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2024 VS 2030 (%)
FIGURE 20. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. AGE-RELATED MACULAR DEGENERATION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. AGE-RELATED MACULAR DEGENERATION MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. AGE-RELATED MACULAR DEGENERATION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY IMPLANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY INTRAVITREAL INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY LASER THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BROLUCIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TRIAMCINOLONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BROLUCIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TRIAMCINOLONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GEOGRAPHIC ATROPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY WET, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SPECIALTY OPHTHALMIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY EARLY, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY INTERMEDIATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY LATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 84. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 86. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 87. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 88. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 89. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 90. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 91. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 92. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 93. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 94. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, 2018-2030 (USD MILLION)
TABLE 95. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 98. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 100. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 101. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 102. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 103. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 104. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 105. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 106. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 107. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 108. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, 2018-2030 (USD MILLION)
TABLE 109. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 111. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 158. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 160. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 161. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 162. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 164. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, 2018-2030 (USD MILLION)
TABLE 166. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 168. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 169. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 171. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 172. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 173. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 174. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 175. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 176. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 177. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 178. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 179. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, 2018-2030 (USD MILLION)
TABLE 180. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 183. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 185. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 186. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 187. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 188. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 189. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 190. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 191. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 192. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 193. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, 2018-2030 (USD MILLION)
TABLE 194. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 196. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 199. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 200. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 201. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 202. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 203. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 204. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 205. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 206. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 207. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, 2018-2030 (USD MILLION)
TABLE 208. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 210. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 211. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 212. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 213. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 214. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 215. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 216. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 217. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 218. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 219. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 220. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 221. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, 2018-2030 (USD MILLION)
TABLE 222. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 223. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 224. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 225. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 226. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 227. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 228. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 229. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 230. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 231. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 232. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 233. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 234. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 235. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, 2018-2030 (USD MILLION)
TABLE 236. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 237. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 238. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 239. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 240. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 241. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 242. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 243. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 244. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 245. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 246. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 247. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 248. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, 2018-2030 (USD MILLION)
TABLE 250. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 251. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 252. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 253. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 254. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 255. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 256. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 257. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 258. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 259. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 260. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 261. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 262. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 263. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, 2018-2030 (USD MILLION)
TABLE 264. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 265. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 266. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 267. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 268. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 269. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 270. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 271. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 272. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 273. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 274. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 275. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 276. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, 2018-2030 (USD MILLION)
TABLE 278. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 279. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 280. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 281. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 282. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 283. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 284. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 285. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 286. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 287. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 288. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 289. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 290. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 291. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, 2018-2030 (USD MILLION)
TABLE 292. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 293. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 294. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 295. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 296. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 297. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 298. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 299. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 300. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 301. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 302. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEG

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Age-related Macular Degeneration market report include:
  • Regeneron Pharmaceuticals, Inc.
  • Bayer AG
  • Novartis AG
  • Roche Holding AG
  • Alcon Inc.
  • Carl Zeiss Meditec AG
  • Topcon Corporation
  • Nidek Co., Ltd.
  • Heidelberg Engineering GmbH
  • Optos plc

Table Information

Report AttributeDetails
No. of Pages192
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 11.82 Billion
Forecasted Market Value ( USD ) by 2030 $ 16.43 Billion
Compound Annual Growth Rate6.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Dry Age-related Macular Degeneration (Dry-AMD)- Pipeline Insight, 2025 - Product Image

Dry Age-related Macular Degeneration (Dry-AMD)- Pipeline Insight, 2025

  • Clinical Trials
  • 240 Pages
  • Global
From
Wet Age-Related Macular Degeneration (Wet-AMD)- Pipeline Insight, 2025 - Product Image

Wet Age-Related Macular Degeneration (Wet-AMD)- Pipeline Insight, 2025

  • Clinical Trials
  • 280 Pages
  • Global
From
Wet Age-Related Macular Degeneration (Wet AMD) Market - A Global and Regional Analysis: Focus on Treatment Type, and Region - Analysis and Forecast, 2025-2035 - Product Image

Wet Age-Related Macular Degeneration (Wet AMD) Market - A Global and Regional Analysis: Focus on Treatment Type, and Region - Analysis and Forecast, 2025-2035

  • Report
  • 100 Pages
  • Global
From
Macular Degeneration Pipeline Analysis Report - Product Image

Macular Degeneration Pipeline Analysis Report

  • Report
  • 150 Pages
  • Global
From
Macular Degeneration Treatment Market Report 2025 - Product Image

Macular Degeneration Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.